# EDGAR Filing Document

**Accession Number:** 0001563577
**File Stem:** 0001193125-26-149590
**Filing Date:** 2026-4
**Character Count:** 5321
**Document Hash:** e11f68eb15968b1a5816e1ba592596ea
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-149590.hdr.sgml**: 20260409

**ACCESSION NUMBER**: 0001193125-26-149590

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 11

**CONFORMED PERIOD OF REPORT**: 20260407

**ITEM INFORMATION**: Other Events

**FILED AS OF DATE**: 20260409

**DATE AS OF CHANGE**: 20260409

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Galera Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001563577
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 461454898
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39114
- **FILM NUMBER:** 26851515

**BUSINESS ADDRESS:**
- **STREET 1:** 101 LINDENWOOD DRIVE
- **STREET 2:** SUITE 225
- **CITY:** MALVERN
- **STATE:** PA
- **ZIP:** 19355
- **BUSINESS PHONE:** 610-725-1500

**MAIL ADDRESS:**
- **STREET 1:** 101 LINDENWOOD DRIVE
- **STREET 2:** SUITE 225
- **CITY:** MALVERN
- **STATE:** PA
- **ZIP:** 19355

?xml version='1.0' encoding='ASCII'? 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of report (Date of earliest event reported): April 7, 2026

## GALERA THERAPEUTICS, INC.

#### (Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39114** | **46-1454898** |
| **(State or other jurisdiction of**<br>**incorporation or organization)** | **(Commission**<br>**File Number)** | **(I.R.S. Employer**<br>**Identification No.)** |

---

#### 101 Lindenwood Drive, Suite 225

#### Malvern, PA 19355

#### (Address of principal executive offices) (Zip Code)
(610) 725-1500

#### (Registrant's telephone number, include area code)

#### N/A

#### (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br>**Symbol(s)** | **Name of each exchange**<br>**on which registered** |
| Common Stock, $0.001 par value per share | GRTX | OTCQB Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 8.01** | **Other Events.** |

---

On April 7, 2026, Galera Therapeutics, Inc. (the "Company") converted 76,479.175 shares of the Company's Series B Non-Voting Convertible Preferred Stock, par value $0.001 per share ("Series B Preferred Stock"), into 76,479,164 shares of the Company's common stock, par value $0.001 per share ("Common Stock"), pursuant to and in accordance with the Certificate of Designation of Preferences, Rights and Limitations of the Series B Non-Voting Convertible Preferred Stock, as amended (the "Certificate of Designation"). No fractional shares of Common Stock were issued in connection with the partial mandatory conversion; in lieu of any fractional shares, the Company will pay each holder an amount in cash equal to the trading value of such fractional shares as of the close of business on the date of the conversion in accordance with the Certificate of Designation. Following the conversion, 42,839.11 shares of Series B Preferred Stock remain issued and outstanding.

In addition, on April 8, 2026, certain affiliates of Ikarian Capital, LLC exercised a portion of their pre-funded warrants to purchase an aggregate of 8,488,229 shares of Common Stock at an exercise price of $0.001 per share, and the related aggregate exercise price of approximately $8,488.23 was paid to the Company. Following the exercise, pre-funded warrants to purchase an additional 14,552,811 shares of Common Stock remain outstanding.

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | GALERA THERAPEUTICS, INC. | GALERA THERAPEUTICS, INC. |
| Date: April 9, 2026 | By: | /s/ J. Mel Sorensen, M.D. |
|  |  | J. Mel Sorensen, M.D. |
|  |  | President and Chief Executive Officer |

---